MME and chronic kidney disease: Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), was added to guidelines for the treatment of HFrEF after the publication of the Prospective comparison of Angiotensin Receptor-neprilysin inhibitor (ARNI) with Angiotensin converting enzyme inhibitor (ACEI) to Determine Impact on Global Mortality and morbidity in Heart Failure (PARADIGM-HF) trial (5) In subgroup analysis, sacubitril/valsartan were found to be superior to enalapril in reducing cardiovascular mortality or HF hospitalization, irrespective of the presence or absence of CKD.